Information Provided By: 
Fly News Breaks for June 12, 2017
CHRS
Jun 12, 2017 | 14:56 EDT
Citi analyst Mohit Bansal, in an intraday follow up note on Coherus Biosciences, lowered his price target on the stock to $33 from $38, stating that the CRL for its Neulasta biosimilar creates uncertainty and delays the product's potential launch by about one year. The analyst, who noted that a positive Supreme Court decision today eliminates a 180 day notice after approval and could expedite launch for the drug by six months, keeps a Buy rating on Coherus shares.
News For CHRS From the Last 2 Days
There are no results for your query CHRS
